CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT – Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 167,688 shares, an increase of 326.9% from the June 15th total of 39,284 shares. Based on an average daily trading volume, of 36,828,063 shares, the short-interest ratio is currently 0.0 days. Approximately 3.9% of the company’s shares are short sold.

CDT Equity Stock Performance

Shares of NASDAQ CDT traded down $0.02 during mid-day trading on Monday, hitting $0.36. The stock had a trading volume of 370,949 shares, compared to its average volume of 3,366,452. CDT Equity has a 1 year low of $0.34 and a 1 year high of $492.00. The business has a 50 day moving average price of $1.03 and a two-hundred day moving average price of $13.12. The firm has a market cap of $1.74 million, a P/E ratio of -0.00 and a beta of 1.49.

Get CDT Equity alerts:

CDT Equity (NASDAQ:CDT – Get Free Report) last announced its quarterly earnings results on Wednesday, April 15th. The company reported $695.11 earnings per share for the quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CDT. Wall Street Zen cut CDT Equity to a “strong sell” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CDT Equity presently has an average rating of “Sell”.

Get Our Latest Stock Analysis on CDT

CDT Equity Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Featured Stories

• Five stocks we like better than CDT Equity
• The SK Hynix IPO and 2027’s AI Memory Squeeze
• Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
• Why Welltower’s Growth Story Might Outrun Its Rich Valuation
• One Short- and One Long-Term ETF for Quantum Computing Bulls

Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.